IL6 and Alzheimer disease: Trebicka et al (2019) demonstrated that, while all patients with AD have some degree of systemic inflammation, patients who go on to develop ACLF have more sustained systemic inflammation, demonstrated by raised IL-6, IL-8, IL-1 receptor antagonist, and human non-mercaptalbumin 2 (31).